April 2020
EU Horizon 2020 grant
LiteVax receives EU Horizon 2020 grant for the development of a next generation of flu vaccines for the globe
Februari 2020
LiteVax part of the consortium for the development of a highly immunogenic HER2-vaccine against breast cancer.
The Eurostars project will support the development of a novel breast cancer HER2 vaccine including the LiteVax Adjuvant. We expect that LVA synergizes with HER2 antigen in the induction of high antibody titers against HER2. These high antibody titers are key for an effective therapeutic HER2 vaccin.
May 2018
LiteVax Joins Dutch Trade Mission to India
For the third time in 2018 LiteVax visited India and joined the Dutch Trade Mission. Prime Minister Mark Rutte and four Ministers were present to support the strategic relationships and economic cooperation. During this important event LiteVax signed 3 MoU's with Indian companies for vaccine development.
February 2018
Business development campaign “Asia First”
LiteVax launches business development campaign “ASIA FIRST’, starting in India and in collaboration with Dutch renowned visual artist Cathelijn van Goor of “Art-Meets-Science” project.
February 20 - 22: Litevax joins the vaccine innovation mission to Delhi, India
February 22 - 24: Litevax attends BioAsia in Hyderabad, India
February 18 - March 6: LiteVax visits private and public vaccine R&D organizations in Asia to discuss proprietary adjuvant technology and to establish collaboration.
February 20 - 22: Litevax joins the vaccine innovation mission to Delhi, India
February 22 - 24: Litevax attends BioAsia in Hyderabad, India
February 18 - March 6: LiteVax visits private and public vaccine R&D organizations in Asia to discuss proprietary adjuvant technology and to establish collaboration.
April 2017
IVW meeting in Lausanne
LiteVax will present data at the Influenza IVW meeting in Lausanne
March 14, 2017
CEPI
LiteVax has become member of the Partners Forum of CEPI, the Coalition for Epidemic Preparedness Innovations.
December 2016
Recent publication
One of the predecessor of LiteVax LVX adjuvant proved to be superior to Freunds’ Complete/Incomplete Adjuvant in large animal species (PMID: 27693642)
November 2016
ADITEC
LiteVax presented its proprietary adjuvant technology at the annual ADITEC meeting in Brussels.
October 2016
FlandersBio Vaccine Conference
LiteVax pitched at the FlandersBio Vaccine Conference in Ghent.
August 2016
Pre-clinical proof
Pre-clinical proof of with inactivated influenza vaccine in relevant ferret model generated highly promising results.
July 2016
ADITEC
LiteVax received an EU commissioned grant from ADITEC (European Union's Seventh Framework Programme Grant Agreement No: 280873) to determine immunological performance of LVA in mice.
May 2016
MVAF
LiteVax presented posters at the MVAF in Copenhagen, Denmark.
April 2016
BVAPS
LiteVax presented posters at the BVAPS in Porto, Portugal.
May 2015
loan
LiteVax received a loan of RedMedTechVenture, an initiative of local authorities.
February 2014
Patent
Patent of new adjuvant molecules filed (WO 2016/013938).
July 2014
proof of concept confirmed
Pre-clinical proof of concept confirmed by experimental malaria recombinant subunit vaccine in rabbits.
July 2013
Oss
LiteVax moved to Pivot Park in Oss, i.e. the former R&D facilities of MSD.
April 2012
CoVaccine BV
LiteVax BV moved into lab facilities of the University of Utrecht and acquired the assets of CoVaccine BV, a company founded some 10 years earlier focusing on synthetic adjuvants for human and veterinary application.
January 2012
EUROSTARS
Together with Radboud University Nijmegen Medical Centre (Nijmegen, NL), Xbrane Biosciences AB (Stockholm, SE), Drug Discovery Factory BV (Amsterdam, NL) LiteVax BV formed a consortium and received a EUROSTARS grant for the development of an intranasal, universal pneumococcal vaccine.
January 2011
Research collaboration
Research collaboration was started with Radboud University Nijmegen Medical Centre (Nijmegen, NL) and Mucosis BV (Groningen, NL) on the use of heteropolymers as adjuvant for an intranasal, universal vaccine against pneumococcal infections.